Cyclamic acid

• UNSPSC Description:

  Cyclamic acid (Cyclamate) is a commonly used sweetener. Cyclamic acid sodium is toxic to osteoblasts and can inhibit cell proliferation, induce apoptosis and reduce cell mineralization. Cyclamic acid sodium causes focal necrosis of bladder organs in rats in vitro, which can promote bladder cancer, but some studies have shown that low doses of Cyclamic acid sodium have no carcinogenic effect. In addition, Cyclamic acid sodium has no effect on insulin and glucagon secretion induced by arginine[1][2][3][4][5].

• Target Antigen:

  Apoptosis; Necroptosis

• Type:

  Reference compound

• Related Pathways:

  Apoptosis

• Field of Research:

  Cancer; Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/cyclamic-acid.html

• Purity:

  98.0

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)|H2O : ≥ 100 mg/mL

• Smiles:

  O=S(O)(NC1CCCCC1)=O

• Molecular Weight:

  179.24

• References & Citations:

  [1]Leban I, et, al. Structures of artificial sweeteners--cyclamic acid and sodium cyclamate with other cyclamates. Acta Crystallogr B. 2007 Jun;63(Pt 3):418-25.|[2]Chen Z, et al. Toxicity of food sweetener-sodium cyclamate on osteoblasts cells. Biochem Biophys Res Commun. 2019 Jan 8;508(2):507-511. |[3]Bopp BA, et al. Toxicological aspects of cyclamate and cyclohexylamine. Crit Rev Toxicol. 1986;16(3):213-306.|[4]Usami M, et al. Effect of cyclamate sodium, saccharin sodium and stevioside on arginine-induced insulin and glucagon secretion in the isolated perfused rat pancreas. Horm Metab Res. 1980 Dec;12(12):705-6.|[5]Knowles MA, et al. Induction of morphological changes in the urothelium of cultured adult rat bladder by sodium saccharin and sodium cyclamate. Carcinogenesis. 1986 May;7(5):767-74.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  100-88-9